注射用DaxibotulinumtoxinA治疗颈部肌张力障碍的疗效与安全性:ASPEN-1 3期随机对照试验
ASPEN-1是一项3期随机双盲安慰剂对照研究,纳入301例中重度颈部肌张力障碍成人患者,随机接受DAXI 125U、250U或安慰剂单次肌内注射。DAXI两个剂量较安慰剂显著改善TWSTRS总分,中位疗效持续时间分别为24.0周和20.3周,安全性与安慰剂相当。
要点
- DAXI 125U和250U较安慰剂显著改善TWSTRS总分,最小二乘均值差分别为-8.5和-6.6。
- DAXI 125U中位疗效持续24.0周,250U为20.3周,均以TWSTRS总分峰值改善丧失≥80%定义。
- 治疗相关不良事件发生率DAXI 125U为29.6%、250U为23.8%、安慰剂为17.4%,注射部位疼痛最常见。
核心结论
- DAXI 125U和250U是治疗颈部肌张力障碍有效、安全、长效且耐受性良好的方案。
研究设计与样本
- ASPEN-1为3期随机双盲安慰剂对照研究,在欧洲和北美9个国家60个中心入组18-80岁中重度颈部肌张力障碍成人(TWSTRS总分≥20)。
- 301例受试者按3:3:1随机接受单次肌内注射DAXI 125U(n=125)、250U(n=130)或安慰剂(n=46),注射后随访至36周。
- 主要终点为第4周和第6周平均TWSTRS总分较基线的变化,采用ANCOVA和Cochran-Mantel-Haenszel分析,并进行多重性校正和多重插补。
主要发现
- DAXI 125U和250U较安慰剂显著改善平均TWSTRS总分,最小二乘均值差(标准误)分别为-8.5(1.93),p<0.0001和-6.6(1.92),p=0.0006。
- 中位疗效持续时间(从治疗至第4周和第6周平均TWSTRS总分峰值改善丧失≥80%的时间)DAXI 125U为24.0周(95%CI 20.3-29.1),250U为20.3周(95%CI 16.7-24.0)。
- DAXI在CGIC和PGIC应答率及TWSTRS子量表评分方面也观察到显著改善。
- 治疗相关治疗中出现的不良事件发生率DAXI 125U为29.6%、250U为23.8%、安慰剂为17.4%,注射部位疼痛总体最常见。
- DAXI 125U、250U和安慰剂组最常报告的治疗相关关注不良事件分别为肌肉无力(4.8%、2.3%、0%)、肌肉骨骼疼痛(2.4%、3.1%、0%)和吞咽困难(1.6%、3.8%、0%)。
关键数值与推荐
- DAXI 125U组较安慰剂组TWSTRS总分最小二乘均值差为-8.5(标准误1.93),p<0.0001。
- DAXI 250U组较安慰剂组TWSTRS总分最小二乘均值差为-6.6(标准误1.92),p=0.0006。
- DAXI 125U组中位疗效持续时间为24.0周(95%CI 20.3-29.1),250U组为20.3周(95%CI 16.7-24.0)。
- 治疗相关不良事件发生率DAXI 125U组29.6%、250U组23.8%、安慰剂组17.4%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety of 2 doses of DaxibotulinumtoxinA for Injection (DAXI), a novel botulinum toxin type A formulation in participants with cervical dystonia (CD). METHODS: Adults (aged 18-80 years) with moderate-to-severe CD (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] total score ≥20) were enrolled at 60 sites across 9 countries in Europe and North America. Participants were randomized (3:3:1) to single-dose intramuscular DAXI 125U, 250U, or placebo and followed for up to 36 weeks after injection. The primary end point was change from baseline in TWSTRS total score averaged across weeks 4 and 6. Key secondary end points included duration of effect, Clinical and Patient Global Impression of Change (CGIC, PGIC), TWSTRS subscale scores, and safety. Multiplicity-adjusted intent-to-treat hypothesis tests with multiple imputation were performed using ANCOVA and Cochran-Mantel-Haenszel analyses. RESULTS: Of 444 individuals screened, 301 were randomized to DAXI 125U (n = 125) or 250U (n = 130) or placebo (n = 46). DAXI 125U and 250U significantly improved the mean TWSTRS total score vs placebo (least squares mean [standard error] difference vs placebo: DAXI 125U, -8.5 [1.93], p < 0.0001; DAXI 250U, -6.6 [1.92], p = 0.0006). The median duration of effect (time from treatment until loss of ≥80% of the peak improvement in average TWSTRS total score achieved at weeks 4 and 6) was 24.0 (95% confidence interval 20.3-29.1) weeks with DAXI 125U and 20.3 (16.7-24.0) weeks with DAXI 250U. Significant improvements were also observed with DAXI in CGIC and PGIC responder rates and TWSTRS subscales. Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.6% of participants with DAXI 125U, 23.8% with DAXI 250U, and 17.4% with placebo, with injection site pain being the most common overall. The most frequently reported treatment-related TEAEs of interest in DAXI 125U, DAXI 250U, and placebo, respectively, were muscular weakness (4.8%, 2.3%, 0%), musculoskeletal pain (2.4%, 3.1%, 0%), and dysphagia (1.6%, 3.8%, 0%). DISCUSSION: This study demonstrated that DAXI, at doses of 125U and 250U, is an effective, safe, long-acting, and well-tolerated treatment for CD. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov identifier (NCT03608397, submitted July 11, 2018) and EU Clinical Trials Register (ClinicalTrialsRegister.eu EudraCT identifier 2018-000446-19, submitted September 13, 2018). First participant enrolled on June 11, 2018. Trial registration was performed in accordance with the Food and Drug Administration Amendments Act (FDAAA 801), which stipulates that the responsible party register an applicable clinical trial not later than 21 calendar days after enrolling the first human participant (42 CFR 11.24). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in adults with moderate-to-severe idiopathic cervical dystonia, DAXI reduces dystonia more effectively than placebo.
引用
- Comella CL, Jankovic J, Hauser RA, et al. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024. PMID: 38295339. doi:10.1212/WNL.0000000000208091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。